Telesis Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 27th of September, 2024.
26 hedge funds and large institutions have $37.3M invested in Telesis Bio, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 2 closing their positions.
147% more capital invested
Capital invested by funds: $15.1M → $37.3M (+$22.2M)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
13% more call options, than puts
Call options by funds: $144K | Put options by funds: $127K
8% more funds holding
Funds holding: 24 → 26 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.82% less ownership
Funds ownership: 42.35% → 40.53% (-1.8%)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Penbrook Management
New York
|
+$145K |
| 2 |
Vontobel Holding
Zurich,
Switzerland
|
+$98.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$54.3K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$36.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
-$1.24M |
| 2 |
Two Sigma Investments
New York
|
-$42.1K |
| 3 |
VF
Virtu Financial
New York
|
-$29K |
| 4 |
Millennium Management
New York
|
-$25.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$9.81K |
TBIO Hedge Fund Activity: Q1 2023 in Review
26 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Telesis Bio, Inc. Common Stock (TBIO) for Q1 2023, worth a combined $37.3M — up 147% from $15.1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TBIO positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was Penbrook Management, adding an estimated $145K. The largest seller was Penn Capital Management, cutting an estimated $1.24M.
- 26 institutional investors held Telesis Bio, Inc. Common Stock (TBIO) as of Q1 2023, up from 24 in Q4 2022.
- Funds reported $37.3M of Telesis Bio, Inc. Common Stock stock for Q1 2023, up 147% quarter-over-quarter.
- 4 funds opened new Telesis Bio, Inc. Common Stock positions in Q1 2023 and 2 closed out, a net change of +2 holders.
- The largest Telesis Bio, Inc. Common Stock buyer in Q1 2023 was Penbrook Management, an estimated $145K added.
- The largest Telesis Bio, Inc. Common Stock seller in Q1 2023 was Penn Capital Management, an estimated $1.24M sold.
Based on aggregated 13F filings for Q1 2023.